tp

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

TP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.

EFdA-TP 3TEA is the salt form of EFdA-TP.EFdA-TP 3TEA is a nucleoside analog that is a novel, potent, and selective nucleoside reverse transcriptase (RT) inhibitor that inhibits HIV-1 reverse transcriptase by multiple mechanisms, thereby increasing its drug resistance.

TP-051 is a potent and selective FFAR1 agonist exhibiting a Ki of 16 nM for human FFAR1, with demonstrated ability to enhance insulin secretion in rat insulinoma cells. TP-051 is widely used as a chemical probe for studying free-fatty-acid receptor-mediated pathways in type 2 diabetes and metabolic research.

TP-050 is a chemical probe, which has oral activity and selectively acts on NMDAR. The EC₅₀ of GluN2A and GluN2D are 0.51 μM and 9.6 μM respectively, and it can penetrate the blood-brain barrier. TP-050 can induce long-term potentiation effect (LTP) in hippocampus, thus promoting neuronal signal transmission.

TP-353 (EOS-61973) is a CDK7 inhibitor.

TP808 is a highly versatile intermediate for the construction of a wide range of tetracycline antibiotics.

TP-2857 (TAP2857) is a potent antimicrobial agent.

TGFβRI-IN-2 is a selective, potent and orally active inhibitor of (Activin-Like Kinase 5) ALK 5(pIC50 and pEC50 values of 7.6 and 6.63, respectively).

TP-004 is a potent, reversible inhibitor of methionine aminopeptidase 2 (MetAP2) with an IC50 of 6 nM.

TP-10 is a selective inhibitor of PDE10A against other PDEs with IC50 of 0.8 nM.

TP-472 is a selective inhibitor of BRD9 (Kd: 33 nM).

TP3011 is a potent topoisomerase I inhibitor equipotent as SN38 and is an active metabolite of CH-0793076.

TP prodrug (compound 15) is an effective and orally active anti-SARS-CoV-2 agent. The 13-TP prodrug exhibits cytotoxic properties and can reduce the expression of the SARS-CoV-2 N protein. Additionally, the 13-TP prodrug demonstrates antiviral activity.

13-TP is an inhibitor of SARS-CoV-2. It effectively suppresses in vitro RNA synthesis catalyzed by the central replication-transcription complex (C-RTC, nsp12-nsp7-nsp82) of SARS-CoV-2. 13-TP fully inhibits RdRp polymerase activity and obstructs the complete extension of some primer RNAs.

TP-2 is a multi-cationic small molecule with a rhomboid shape, serving as an antidote capable of fully neutralizing unfractionated heparin (UFH) and low molecular weight heparin (LMWH). It surpasses protamine in neutralization efficacy and is also biocompatible.

TP receptor antagonist-3 (compound 51280) is a potent antagonist of the thromboxane A2 prostaglandin (TP) receptor, exhibiting an IC50 of 15.7 nM for Human TP. This compound is applicable in research related to Alzheimer's disease, cardiovascular and respiratory disorders, as well as cancer studies.

ALS-8112-TP is the 5'-triphosphate metabolite of ALS-8112. This compound acts as a potent, selective, and competitive inhibitor of respiratory syncytial virus (RSV) RNA polymerase, demonstrating selectivity over host or unrelated viral polymerases, such as the hepatitis C virus (HCV). It is efficiently recognized by the recombinant RSV polymerase complex, resulting in the termination of RNA synthesis. ALS-8112-TP is applicable in the research of RSV infections.

TP003 is a novel non-selective GABAA receptor benzodiazepine site agonist with affinity for α1β2gam2, α2β3gam2, α3β3gam2, α5β2gam2, EC50 of 20.3, 10.6, 3.24, 5.64 nM, respectively. TP003 has antianxiety and partial anticonvulsant activity via the α2GABAA receptor.

TP-0427736 is a novel potent and selective ALK5 inhibitor (IC50: 2.72 nM). P0427736 was 300-fold higher than the inhibitory effect on ALK3. TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates the anagen phase i

TP-064 is a potent and selective PRMT4 inhibitor, featuring an IC50 < 10nM for methylation of H3 (1-25) and over 100-fold selectivity compared to other histone methyltransferases and non-epigenetic targets. It inhibits the methylation of MED12 in cells with an IC50 of 43 nM.

TP-271, a tetracyclines antibiotic, is used potentially for the treatment of community-acquired bacterial pneumonia (CABP).

TP-680 is a antagonist of cholecystokininA receptor.

TP-238, a potent and selective dual CECR2/BPTF probe, exhibits IC50 values of 30 nM and 350 nM, respectively. Additionally, it inhibits BRD9 with a pIC50 of 5.9, demonstrating lesser activity against another 338 kinases [1] [2].